TUDORZA PRESSAIR consists of a dry powder formulation of aclidinium bromide for oral inhalation only.
Aclidinium bromide, the active component of TUDORZA PRESSAIR is an anticholinergic with specificity for muscarinic receptors.
TUDORZA™ PRESSAIR™ (aclidinium bromide inhalation powder) is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Published Studies Related to Tudorza Pressair (Aclidinium Bromide)
Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase
I study. 
ability to reduce methacholine-induced bronchoconstriction... CONCLUSION: Aclidinium produced statistically significant and sustained
Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic
antagonist, in COPD patients. 
doses of aclidinium bromide in patients with COPD... CONCLUSION: Aclidinium bromide 100-900microg produced sustained bronchodilation
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. 
CONCLUSION: Aclidinium bromide is an inhaled anticholinergic that improves lung
Safety and pharmacokinetics of single doses of aclidinium bromide, a novel
long-acting, inhaled antimuscarinic, in healthy subjects. 
tolerability, safety and pharmacokinetics of aclidinium in healthy subjects... CONCLUSIONS: Aclidinium appears to be safe and well tolerated in single doses of
Page last updated: 2014-12-01